Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $33.3333.

Several research analysts recently commented on the stock. Guggenheim increased their target price on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday. Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. upped their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Finally, Wells Fargo & Company decreased their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th.

Insider Transactions at Monte Rosa Therapeutics

In other news, insider Philip Nickson sold 5,845 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $17.69, for a total transaction of $103,398.05. Following the completion of the sale, the insider owned 55,000 shares of the company’s stock, valued at approximately $972,950. This represents a 9.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Anthony M. Manning sold 10,000 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the sale, the director owned 10,000 shares of the company’s stock, valued at $231,100. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 81,623 shares of company stock worth $1,732,119. Corporate insiders own 6.40% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC acquired a new position in Monte Rosa Therapeutics in the 4th quarter worth about $30,000. Russell Investments Group Ltd. bought a new position in shares of Monte Rosa Therapeutics during the third quarter valued at $32,000. Lazard Asset Management LLC grew its stake in shares of Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after purchasing an additional 3,262 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after purchasing an additional 451 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after buying an additional 776 shares during the period. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Price Performance

NASDAQ:GLUE opened at $24.21 on Friday. Monte Rosa Therapeutics has a fifty-two week low of $4.12 and a fifty-two week high of $25.77. The business’s 50-day simple moving average is $19.37 and its 200-day simple moving average is $18.88. The stock has a market capitalization of $2.05 billion, a PE ratio of -16.36 and a beta of 1.56.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. On average, research analysts expect that Monte Rosa Therapeutics will post -1.23 earnings per share for the current year.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.